The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: The purpose of this study was to examine the association between atypical antipsychotics, including the newer agents, aripiprazole and ziprasidone, and newly treated diabetes, using the largest post‐marketing cohort of patients exposed to these newer treatments that has been studied to date. Methods: Identified two overlapping cohorts—a simple cohort (all antipsychotic users) and an inception cohort (new users of antipsychotics)—using automated data from three United States sites (60.4 million covered lives). Patients exposed to antipsychotics ≥ 45 days were identified and followed for incident diagnoses of treated diabetes. Data analysis accounted for drug switching and non‐consistent drug use. Results: In the 55 287‐member inception cohort, 357 cases of newly treated diabetes were identified. Compared with current use of typical antipsychotics, current users of aripiprazole (adjusted hazard ratio (aHR) 0.93, 95% confidence interval (CI) 0.50–1.76), quetiapine (aHR 1.04, 95%CI, 0.67–1.62), risperidone (aHR 0.85, 95%CI, 0.54–1.36) and ziprasidone (aHR 1.05, 95%CI, 0.54–2.08) had similar low risk of diabetes. Patients exposed to olanzapine had an increased risk of diabetes (aHR 1.71, 95%CI, 1.12–2.61), and although the effect estimate is imprecise, clozapine‐exposed patients had a trend towards an elevated hazard ratio (aHR 2.58, 95%CI, 0.76–8.80). Results for the simple cohort were similar. Conclusions: Relative to typical antipsychotics, aripiprazole, ziprasidone, risperidone and quetiapine were not associated with an increased risk of diabetes; olanzapine and clozapine were associated with an increased risk. This analysis constitutes the largest post‐marketing pharmacoepidemiologic study to date that includes the newer agents. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421 · cited 1×
“Several retrospective pharmacoepidemiologic studies report a higher risk of diabetes in patients treated with atypical antipsychotic drugs compared with either a general population cohort or untreated psychosis patients.(3,11,14) Further, the reported incidence of diabetes is higher among those taking atypical antipsy…”
BackgroundSelf-citation
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“Of the atypical AP, specifically olanzapine (231-234)”
BackgroundSelf-citationMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“creased risk of glucose dysregulation or DM in people who have schizophrenia or bipolar disorder (28,62) (Table 2).”
BackgroundMitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
“…recognized that most antipsychotic agents are closely linked with adverse effects on weight, lipids and glucose metabolism and cardiovascular disease (Jin et al. 2004 ; Meyer & Koro, 2004 ; Newcomer, 2005 ; Oriot et al. 2008 ; Smith et al. 2008 ; Yood et al. 2009 ; Crossley et al. 2010).”
BackgroundNielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Metadata
- Authors
- Yood, M. U., deLorenze, G., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Willey, V. J., McQuade, R., Newcomer, J., & L'Italien, G.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2009-08-18
- Volume
- 18
- Issue
- 9
- Pages
- 791-799
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2089272346
- Cited by
- 103
- References
- 3
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study. https://app.cochat.ai/papers/10.1002/pds.1781
- The paper
- Yood, M. U., deLorenze, G., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Willey, V. J., McQuade, R., Newcomer, J., & L'Italien, G. (2009). The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.1781
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.